@article{TLCR121950,
author = {Jialiang Wen and Yuzhou Wang and Tao Wang and Tao Chen and Yichen Dong and Jingyu Chen and Long Xu and Jiajun Deng and Yunlang She and Junqi Wu and Lei Jiang and Diego Gonzalez-Rivas and Xuefei Hu and Chang Chen and Chenlu Yang},
title = {Extended sleeve lobectomy after neoadjuvant chemo-immunotherapy: postoperative outcomes differ by surgical side},
journal = {Translational Lung Cancer Research},
volume = {15},
number = {8},
year = {2026},
keywords = {},
abstract = {Background: Centrally located non-small cell lung cancer (NSCLC) has traditionally been managed by pneumonectomy (PN), while sleeve lobectomy has emerged as a parenchyma-sparing alternative. With neoadjuvant chemo-immunotherapy now standard for locally advanced NSCLC, the role of extended sleeve lobectomy in this setting remains unclear. The study evaluated whether extended sleeve lobectomy (ESL) could bring benefits to the NSCLC patients eligible for the procedure after neoadjuvant chemo-immunotherapy.
Methods: Three hundred and thirty-five centrally located NSCLC patients who underwent sleeve lobectomy or PN following neoadjuvant immunotherapy plus chemotherapy in Shanghai Pulmonary Hospital were retrospectively reviewed. The population was divided into three groups: the ESL, the simple sleeve lobectomy (SSL), and the PN groups. Short-term perioperative outcomes, event-free survival (EFS), and overall survival were compared among the three groups in the overall, left-sided, and right-sided cohorts, respectively.
Results: In the overall cohort, baseline characteristics showed no significant differences among the three groups, except for the surgical side (P},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/121950}
}